1. PET/CT and MR improve interobserver agreement in primary tumor determination for radiotherapy in esophageal squamous cell cancerAjra Šečerov Ermenc, Primož Peterlin, Vaneja Velenik, Ana Jeromen, Jasna But-Hadžić, Franc Anderluh, Barbara Šegedin, 2025, original scientific article Abstract: The aim of the study was to evaluate interobserver variability in the determination of the primary tumor for radiotherapy treatment planning in esophageal squamous cell carcinoma (ESCC). Methods: Sixteen patients with locally advanced ESCC were included in the analysis. In all patients positron emission tomography with computed tomography (PETC/CT) and magnetic resonance (MR) scans for radiotherapy planning were performed. Five experienced radiation oncologists delineated the primary tumor based on CT alone, MR alone, PET/CT, CT with fused MR and PET/CT with fused MR. Mean tumor volumes were calculated for each patient and imaging modality. The generalized conformity index (CIgen) was calculated to assess agreement in tumor determination. Results: The mean tumor volumes and CIgen for CT alone, MR alone, PET/CT, CT with fused MR and PET/CT with fused MR were 33.1 cm3, 30.2 cm3, 38.1 cm3, 31.9 cm3, 36.2 cm3 and 0.59, 0.64, 0.66, 0.63, 0.71, respectively. CIgen was significantly higher using PET/CT with fused MR compared to CT (p < 0.001) and PET/CT (p = 0.002) and using PET/CT compared to CT (alone) (p = 0.003). Conclusions: Our study showed higher agreement in primary tumor determination in ESCC using PET/CT compared to CT alone. Higher agreement was also found using PET/CT with fused MR compared to CT alone and PET/CT.
Keywords: magnetic resonance, positron emission tomography, squamous cell carcinoma, primary tumor
Published in DiRROS: 26.11.2025; Views: 527; Downloads: 259
 Full text (566,23 KB)
This document has many files! More... |
2. Kapecitabin med obsevanjem : bolnikov dnevnikJanja Ocvirk, Vaneja Velenik, Irena Oblak, Franc Anderluh, Jasna But-Hadžić, Ajra Šečerov Ermenc, Martina Reberšek, Marko Boc, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Tanja Mesti, 2014, not set Keywords: citostatiki, kapecitabin, bolniki, obsevanje
Published in DiRROS: 02.09.2025; Views: 562; Downloads: 223
 Link to file |
3. Priporočila za sistemsko onkološko in radioterapevtsko zdravljenje rakov biliarnega traktaErik Brecelj, Martina Reberšek, Ajra Šečerov Ermenc, Vesna Zadnik, Maja Ebert Moltara, Nežka Hribernik, Peter Korošec, Tanja Mesti, Janja Ocvirk, Franc Anderluh, Marko Boc, Marija Ignjatović, Ana Jeromen, Irena Oblak, Vaneja Velenik, Jelena Azarija, Neva Volk, Nena Golob, 2025, professional article Abstract: Raki biliarnega trakta so redka in heterogena skupina z naraščajočo incidenco in visoko umrljivostjo. Imajo slabo prognozo s celokupnim preživetjem manj od 1 leta. Nova dognanja o molekularno genetski heterogenosti rakov biliarnega trakta in novi terapevtskih pristopi omogočajo tem bolnikom daljša preživetja in boljšo kvaliteto življenja. V Priporočilih so predstavljena najnovejša priporočila za sistemsko onkološko zdravljenje in radioterapijo te skupine rakov, med katere po mednarodnih propročilih sedaj prištevamo karcinom žolčnika, intrahepatalne holangiokarcinome in ekstrahepatične holangiokarcinome, s perihilarnim holangiokarcinomom in karcinomom distalnega žolčevoda. Priporočila za sistemsko zdravljenje so povzeta in pripravljena na podlagi mednarodnih priporočil, ameriških, National Comprehensive Cancer Network (NCCN) in evropskih, Evropskega združenja za internistično onkologijo – European Society of Medical oncology (ESMO).
Keywords: raki biliarnega trakta, sistemsko zdravljenje, priporočila
Published in DiRROS: 18.07.2025; Views: 791; Downloads: 324
Full text (125,57 KB) |
4. |
5. |
6. |
7. Definitive radiochemotherapy in esophageal cancer : a single institution experienceFranc Anderluh, Miha Toplak, Vaneja Velenik, Irena Oblak, Ajra Šečerov Ermenc, Ana Jeromen, Jasna But-Hadžić, Marija Skoblar Vidmar, 2019, original scientific article Keywords: radiochemotherapy, definitive radiochemotherapy, esophageal cancer
Published in DiRROS: 05.07.2024; Views: 1288; Downloads: 394
Full text (413,38 KB) |
8. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in SloveniaMojca Tuta, Nina Boc, Erik Brecelj, Mirko Omejc, Franc Anderluh, Ajra Šečerov Ermenc, Ana Jeromen, Irena Oblak, Bojan Krebs, Vaneja Velenik, 2019, original scientific article Keywords: total neoadjuvant treatment, radiochemotherapy, rectal cancer
Published in DiRROS: 05.07.2024; Views: 1307; Downloads: 477
Full text (369,90 KB) |
9. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer : long-term results of phase II OIGIT-01 TrialDanijela Golo, Jasna But-Hadžić, Franc Anderluh, Erik Brecelj, Ibrahim Edhemović, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Šečerov Ermenc, Vaneja Velenik, 2018, original scientific article Abstract: The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1.8 Gy daily fraction. The doses of concomitant and neo/adjuvant capecitabine were 825 mg/m2/12h and 1250mg/m2/12h, respectively. The primary endpoint was pathologic complete response (pCR). Results Forty-three (65.1%) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant chemotherapy were 98.5%, 93.8% and 87.3%, respectively. CRT was completed by 65/66 patients, with G % 3 non-hematologic toxicity at 13.6%. The rate of pCR (17.5%) was not increased, but N and the total-down staging rates were 77.7% and 79.3%, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR) (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 64.0% (95% CI 63.89%64.11) and 69.5% (95% CI 69.39%69.61), respectively. Conclusions In LARC preoperative treatment intensification with capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.
Keywords: rectal cancer, neoadjuvant chemotherapy, preoperative chemoradiotherapy
Published in DiRROS: 11.06.2024; Views: 1430; Downloads: 869
Full text (1,27 MB)
This document has many files! More... |
10. Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general Slovenian populationVaneja Velenik, Ajra Šečerov Ermenc, Jasna But-Hadžić, Vesna Zadnik, 2017, original scientific article Abstract: The aim of our study was to obtain reference data of the EORTC QLQ-C30 quality of life dimensions for the general Slovenian population. We intend to provide the researchers and clinicians in our country with the expected mean health-related quality of life (HRQL) scores for distinctive socio-demographic population groups. Methods. The EORTC QLQ-C30 questionnaire supplemented by a socio-demographic inquiry was mailed or distributed to 1,685 randomly selected individuals in the Slovenian population aged 18 % 90. Answers from 1,231 subjects representing socio-demographic diversity of the Slovenian population were collected and transformed into EORTC dimensions and symptoms. The impact of socio-demographic features on HRQL scores was assessed by multiple linear regression models. Results. Gender, age and self-rated social class are the important confounders in the quality of life scores in our population. Men reported better quality of life on the majority of the specific scales and, at the same time, reported fewer symptoms. There was no gender-specific difference in cognitive functioning. The mean scores were consistently lower with age in both sexes. Conclusions. This is the first study to report the normative EORTC QLQ-C30 scores for one of the south-eastern European populations. The reported expected mean scores allow Slovenian oncologists to estimate what the quality of life in cancer patients would be, had they not been ill. As they are derived by common methodology, our results can easily be included in any further international comparisons or in the calculation of European summarized HRQL scores.
Published in DiRROS: 24.05.2024; Views: 1265; Downloads: 441
Full text (570,58 KB) |
